Table of Contents Author Guidelines Submit a Manuscript
Erratum

An erratum for this article has been published. To view the erratum, please click here.

Dermatology Research and Practice
Volume 2018, Article ID 1284687, 5 pages
https://doi.org/10.1155/2018/1284687
Research Article

From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution

Scleroderma Unit, Chair of Rheumatology, University of Modena and Reggio Emilia, Modena, Italy

Correspondence should be addressed to Giuggioli Dilia; moc.liamtoh@iloigguigailid

Received 9 October 2017; Revised 6 December 2017; Accepted 28 December 2017; Published 30 January 2018

Academic Editor: Jag Bhawan

Copyright © 2018 Giuggioli Dilia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Ferri, M. Sebastiani, A. Lo Monaco et al., “Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature,” Autoimmunity Reviews, vol. 13, no. 10, pp. 1026–1034, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. L. S. Peterson, A. M. Nelson, W. P. Su et al., “The epidemiology of Morphea (localized scleroderma) in Olmstead Country 1960-1993,” The Journal of Rheumatology, vol. 24, pp. 73–80, 1997. View at Google Scholar
  3. N. Fett and V. P. Werth, “Update on morphea: Part I. Epidemiology, clinical presentation, and pathogenesis,” Journal of the American Academy of Dermatology, vol. 64, no. 2, pp. 217–228, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. F. Careta and R. Romiti, “Localized scleroderma: Clinical spectrum and therapeutic update,” Anais Brasileiros de Dermatologia, vol. 90, no. 1, pp. 62–73, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Goldsmith, S. Katz, B. Gilchrest et al., Flitzpatrick’s Dermatology in General Medicine, McGraw-Hill Education, 8th edition, 2012.
  6. L. S. Peterson, A. M. Nelson, and W. P. D. Su, “Classification of morphea (localized scleroderma),” Mayo Clinic Proceedings, vol. 70, no. 11, pp. 1068–1076, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Bielsa Marsol, “Update on the Classification and Treatment of Localized Scleroderma,” Actas Dermo-Sifiliográficas (English Edition), vol. 104, no. 8, pp. 654–666, 2013. View at Publisher · View at Google Scholar
  8. N. Birdi, R. M. Laxer, P. Thorner, M. J. Fritzler, and E. D. Silverman, “Localized scleroderma progressing to systemic disease. case report and review of the literature,” Arthritis & Rheumatism, vol. 36, no. 3, pp. 410–415, 1993. View at Publisher · View at Google Scholar · View at Scopus
  9. F. J. Mayorquin, T. L. McCurley, and J. E. Levernier, “Progression of childhood linear scleroderma to fatal systemic sclerosis,” The Journal of Rheumatology, vol. 21, pp. 1955–1957, 1994. View at Google Scholar
  10. F. van den Hoogen, D. Khanna, J. Fransen et al., “Classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative,” Annals of the Rheumatic Diseases, vol. 72, pp. 1747–1755, 2013. View at Google Scholar
  11. M. Cutolo, C. Pizzorni, M. Tuccio et al., “Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis,” Rheumatology, vol. 43, no. 6, pp. 719–726, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Gorkiewicz-Petkow and A. Kalinska-Bienias, “Systemic involvement in localized scleroderma/morphea,” Clinics in Dermatology, vol. 33, no. 5, pp. 556–562, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Dehen, J.-C. Roujeau, A. Cosnes, and J. Revuz, “Internal involvement in localized scleroderma,” Medicine (United States), vol. 73, no. 5, pp. 241–245, 1994. View at Google Scholar · View at Scopus
  14. H. R. Maricq, “Capillary Abnormalities, Raynaud's Phenomenon, and Systemic Sclerosis in Patients with Localized Scleroderma,” JAMA Dermatology, vol. 128, no. 5, pp. 630–632, 1992. View at Publisher · View at Google Scholar · View at Scopus
  15. J. K. Chen, L. Chung, and D. F. Fiorentino, “Characterization of patients with clinical overlap of morphea and systemic sclerosis: A case series,” Journal of the American Academy of Dermatology, vol. 74, no. 6, pp. 1272–1274, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Toki, S.-I. Motegi, K. Yamada et al., “Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma,” The Journal of Dermatology, vol. 42, no. 3, pp. 283–287, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Soma, T. Tamaki, K. Kikuchi et al., “Coexistence of morphea and systemic sclerosis,” Dermatology, vol. 186, no. 2, pp. 103–105, 1993. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Hayashi, Y. Ichiki, and Y. Kitajima, “Coexistence of recurrent generalized morphea and systemic sclerosis,” Acta Dermato-Venereologica, vol. 89, no. 3, pp. 329-330, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. K. Sharma, M. P. Sawhney, and S. Srivastava, “Systemic sclerosis, localized morphea, en coup de sabre and aortic regurgitation: a rare association,” Indian Journal of Dermatology, Venereology and Leprology, vol. 70, pp. 99–101, 2004. View at Google Scholar
  20. D. Lipsker, D. Bessis, A. Cosnes et al., “Prospective evaluation of frequency of signs of systemic sclerosis in 76 patients with morphea,” Clinical and Experimental Rheumatology, vol. 33, Suppl. 91, no. 4, pp. S23–S25, 2015. View at Google Scholar